Perth-based biotechnology company PharmAust has clinched an agreement with the Walter and Eliza Hall Institute for research into the effectiveness of its monepantel drug against a cancer-inducing virus in humans. The research raises hopes for an effective treatment for 10-to-20 million people worldwide infected with the HTLV-1 virus, which causes pulmonary disease, inflammatory disorders and, in some cases, leukaemia or lymphoma.